DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Actelion
Actelion
From the Academy
Annual Report on Annual Reports 2016
Sales of $20.7 Billion Reflecting Growth of 1.9%, Operational Growth of 3.2
FDA Listing of Authorized Generics As of July 1, 2021
Annual Report
Johnson & Johnson Annonce Que L'exécution De L'offre Publique D
HIGHLIGHTS of PRESCRIBING INFORMATION TRACLEER® (Bosentan) Tablets These Highlights Do Not Include All the Information Needed to Use TRACLEER Safely and Effectively
2016 Annual Report
Partner with DNA
Swiss Biotech Success Stories Award Winner 2020 Actelion
Selected Pharmaceuticals in Late Stage U.S. and E.U
95879-Medadnews-Nove
Research Annual Report
Johnson & Johnson
Appendix B - Product Name Sorted by Applicant
Manufacturers and Wholesalers Street City ST Zip Acorda Therapeutics
Results from Randomized Phase II Core and Extension Studies in Relapsing‑Remitting Multiple Sclerosis Mark S
Cancellation of Publicly Held Actelion Shares and Delisting from SIX Swiss Exchange As of November 7, 2017
Top View
Drug Companies Participating in MED-Project Stewardship Plan (February 9, 2017)
Actelion Follows Innovation Into GP Markets Switzerland’S Actelion Has Become Europe’S Most Successful Biotech in Large Part Thanks to PAH Treatment Tracleer
Abbott Abbvie Acpeth Actelion Pharmaceuticals Air Liquide
FULL NAME Contact Company ID Email 3M Company Suzanne Danielson CC0013
[email protected]
3M Unitek Corporation Vincent Martinez CC0361
[email protected]
A-Dec, Inc
Affiliate Rewards Eligible Companies
Idorsia Announces Financial Results for the First Half 2021 – Building Momentum Towards Becoming a Fully-Fledged Biopharmaceutical Company
Clarity on Mergers & Acquisitions
For Relapsing Forms of Multiple Sclerosis
TRACLEER (Bosentan)
J&J / Actelion Regulation
Offer Prospectus English
Johnson & Johnson
Idorsia Financial Report 2020
Financial Report Full Year 2017
J&J's $30Bn for Actelion Buys Immediate and Longer-Term Value
Johnson & Johnson
Provider Manual
Questionnaire on Johnson and Johnson Products
1:20-Cv-03471 Document #: 370 Filed: 02/03/21 Page 1 of 27 Pageid #:27504
2020 Annual Report • • Failure to Meet Compliance Obligations in the Mcneil-PPC, Inc
Johnson & Johnson Announces Completion of Acquisition of Actelion
Johnson & Johnson to Acquire Actelion for $30Bn in Cash
Company Profiles 2009
Overview of Ftc Actions in Pharmaceutical Products and Distribution*
JNJ Earnings Presentation
Johnson & Johnson
Johnson & Johnson
Janssen Announces U.S. FDA Approval of PONVORY™ (Ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Pro…
Efficacy of Varenicline Combined with Nicotine Replacement Therapy Vs Varenicline Alone for Smoking Cessation a Randomized Clinical Trial
For a Healthier World
Study Protocol AC-078A201
06001 Preliminary Program New Colors.Qxp
Idorsia Company Fact Sheet
New Patented Medicines Reported to Pmprb - 2002 (Update As of May 31, 2011 - Highlighted)
EXHIBIT 21 SUBSIDIARIES Johnson & Johnson, a New Jersey
Earnings Presentation
Executive Summary
Actelion: Creating Value Together
Zavesca, INN- Miglustat
Who's Who in Biotech
Actelion Enters Into an Agreement to Acquire Privately-Held Ceptaris Therapeutics VALCHLOR™ Gel Under FDA Review for Early-Sta